Bank Pictet & Cie Europe AG Grows Position in Eli Lilly and Company (NYSE:LLY)

Bank Pictet & Cie Europe AG grew its holdings in Eli Lilly and Company (NYSE:LLY) by 1.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,190 shares of the company’s stock after acquiring an additional 705 shares during the period. Eli Lilly and Company comprises about 1.3% of Bank Pictet & Cie Europe AG’s investment portfolio, making the stock its 22nd biggest position. Bank Pictet & Cie Europe AG’s holdings in Eli Lilly and Company were worth $55,097,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Lynx Investment Advisory bought a new stake in Eli Lilly and Company during the second quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $36,000. Cedar Mountain Advisors LLC lifted its holdings in Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after buying an additional 16 shares during the period. Morton Brown Family Wealth LLC lifted its holdings in Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Unique Wealth Strategies LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $45,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 0.7 %

NYSE LLY opened at $902.96 on Thursday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company’s 50 day simple moving average is $921.12 and its 200 day simple moving average is $860.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a market capitalization of $858.18 billion, a P/E ratio of 132.98, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Equities research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on LLY shares. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Barclays lifted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.